PFE's Quality Score rose 1 point on Tue, Nov 10, to 17. It closed near its high of the day (2 chart checks started).
Follow PFE's trial news. Pro members can get an alert when Pfizer files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 2% on Nov 3, and still 5% under its Nov 2 close.
“The operational decrease was driven by a decline in revenues from COVID-19 products, the Prevnar family and several other products across categories”
| Outperforming | Up 13% in 6 months vs the S&P's +2% |
| Its score | Up:Excellent or better for 20 days in a row |
| Latest filing | 8-K, Nov 3 |
Fri Nov 6Novo, Pfizer make CFO hires; Alnylam's chief commercial officer exits as struggles continue
Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO
PFE closed +2.6% the next session (Nov 4) on 1.5x normal volume.
Tue Nov 17: Jefferies 17th Annual London Global…Investor conference · date confirmed.
Expected to report Tue Feb 2, before the open
CEO Albert Bourla bought 38,000 shares on Aug 12. 4 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Excellentfor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
PFE is #3 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score |
Net income over four quarters: PFE $4.03B, ZTS $2.51B, MRK $2.45B.
Expected to report Tue Feb 2, before the open (in 84 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The operational decrease was driven by a decline in revenues from COVID-19 products, the Prevnar family and several other products across categories, largely offset by an increase in revenues for Eliquis, Padcev, the Vyndaqel family, Nurtec, Lorbrena and several other products across categories.”
PFE's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Revenue | $62B to $64B |
“Third-quarter 2026 R&D Expenses (4) increased 18% operationally compared to the prior-year quarter, driven primarily by an anticipated net increase in spending in certain oncology and obesity product candidates, as well as an increase in compensation-related expenses in the quarter.”
From its results filing (SEC filing · Nov 3)
Sales grew 8.5% a year over 5 years, fiscal 2020 to 2025.
Pays $1.72 a share a year.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | +0.0% | -2.2% | -4.7% |
| Aug 4, 2026 | +0.0% | +1.5% | +8.1% |
| May 5, 2026 | +1.1% | +0.6% | -1.9% |
Sales grew in three of the last five years, to $63B in 2025. It made a profit in each of the six years.
RSI 49.4, MACD below signal, above both averages. Not scored.
Its dividends come to 84% of its free cash flow.
| Dividend | $1.72 a share a year |
| Paid out | About $9.9B a year |
| Free cash flow | $12B |
3 insiders bought $3M across 3 filings, and one insider sold $135K across 2 filings, in the last 6 months. The newest:
23 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: PFE is 0.7% of VYM, 0.3% of VOO, and 0.3% of SPYI, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Jul 31, 2026.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
“Our business is conducted in intensely competitive and highly regulated markets.”
PFE scores 17 today, which Breakaway calls Excellent. It is #3 of 90 in Pharma by Quality Score, with 6 of 14 chart checks firing. Down 2% on Nov 3, and still 5% under its Nov 2 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
PFE scores 17 today, which Breakaway calls Excellent (15 to 19). That is #3 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PFE's 17.
3 insiders bought $3M across 3 filings, and one insider sold $135K across 2 filings, in the last 6 months. The newest is Albert Bourla, Chairman & CEO, who bought $1M on Aug 12. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.